You are here: Industry Insights > Indivumed

News List

Veraxa Biotech and Indivumed to Jointly Develop Precision Oncology Antibody Drugs contractpharma
August 11, 2021
Veraxa Biotech GmbH and Indivumed GmbH have entered an agreement to jointly discover modulatory and functional antibodies against several targets that are relevant for colorectal cancer.
VERAXA Biotech and Indivumed Cooperate on the Development of Precision Oncology Antibody Drugs b3cnewswire
August 11, 2021
VERAXA Biotech GmbH, Heidelberg, and Indivumed GmbH, Hamburg, announced today their agreement to jointly discover modulatory and functional antibodies against several targets that are relevant for colorectal cancer.
Indivumed Launches the nRavel AI Platform for Cancer Research and Drug Development firstwordpharma
June 03, 2021
Indivumed GmbH ("Indivumed") today announced the launch of nRavelTM, a unique AI discovery platform for oncology and precision medicine.
Evotec & Indivumed Enter Research Collaboration ontractpharma
April 15, 2019
To discover and develop first-in-class therapeutics for the treatment of colorectal cancer.
Indivumed, IMCB to build multiomics cancer database biospectrumasia
July 09, 2018
This contributes to Indivumed's global cancer database solution IndivuType, funded by the European Investment Bank and private investors.
Indivumed partners with cancer research specialist Helomics biospectrumasia
September 25, 2017
This partnership will allow customers of both companies to benefit from a joint offering of Indivumed’s leading Cancer Database, biobank and world class research laboratory in Europe